GlassScriptPhysician profile
Adam Lance Rubinstein
NPI 1174588909
$4,252.69
in general payments reported to CMS, 2019-2025
29 companies · $758 in 2025
The $758 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $540 · 2020: $409 · 2021: $623 · 2022: $537 · 2023: $790 · 2024: $596 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,144.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $688.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $628.71 | 2019-2024 | Qulipta, Synthroid, Vraylar |
| Pfizer INC. | $570.56 | 2019-2025 | |
| Glaxosmithkline, LLC. | $542.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $299.78 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Merck Sharp & Dohme LLC | $182.78 | 2019-2025 | Gardasil 9, Vaxneuvance, Gardasil |
| Exact Sciences Corporation | $146.13 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $145.77 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.34 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $117.02 | 2019-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.69 | 2019-2024 | Jardiance |
| Antares Pharma, INC. | $88.26 | 2025 | Xyosted |
| Amgen INC. | $78.65 | 2024-2025 | Repatha, Otezla, Repatha |
| Insulet Corporation | $60.47 | 2022-2023 | Omnipod |
| Janssen Pharmaceuticals, INC | $59.48 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $58.62 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $50.24 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $47.03 | 2022-2023 | Quviviq |
| Sanofi Pasteur INC. | $37.79 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $32.54 | 2022 | |
| Esperion Therapeutics, INC. | $29.42 | 2022 | |
| Inspire Medical Systems, INC. | $26.82 | 2025 | Inspire |
| Axsome Therapeutics, INC. | $19.73 | 2025 | Auvelity |
| Gilead Sciences, INC. | $17.50 | 2025 | |
| Allergan, INC. | $17.19 | 2019 | |
| Eisai INC. | $16.76 | 2021 | |
| Abbott Laboratories | $16.55 | 2019 | |
| Amneal Pharmaceuticals LLC | $15.55 | 2021 | |
| Ironshore Pharmaceuticals INC. | $15.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Rubinstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.